Abstract
Sarcoidosis is a multisystem disease characterized histologically by the presence of non-caseating epithelioid cell granulomas. Although the etiology of sarcoidosis remains uncertain, Cutibacterium acnes (formerly known as Propionibacterium acnes) and mycobacteria are considered putative pathogenic antigens in sarcoidosis. Sarcoidosis must be differentiated from a variety of granulomatous diseases of the lung. The granulomas in pulmonary sarcoidosis are frequently located in the broncho-vascular bundles, interlobular septa, and alveoli, and there is frequent vascular involvement in the form of granulomatous angiitis. While most granulomas may spontaneously or with treatment disappear, some along the broncho-vascular bundles and interlobular septa often become fibrotic. In the chronic fibrotic stage, the upper lobes of the lungs become scarred and contracted, with fibrous bands seen between the hilar regions and pleura. Cystic changes and, occasionally, honeycombing are seen in the lung. Granulomatous vascular involvement is frequently seen in the lung. The microangiopathy of sarcoidosis is characterized by endothelial injury and multilamellation of the basement membrane of microvessels and has been observed electron microscopically in the heart, lung, eye, and skin specimens. The pathogenetic correlation between granulomas and microangiopathy remains to be resolved.
1 Introduction
Sarcoidosis is a multisystem disease that affects multiple organs and is characterized by non-caseating epithelioid cell granulomas in the affected organs (1). The precise etiology of sarcoidosis remains unknown, and many pathogens, including mycobacteria, have been implicated over the years.
In Japan, Cutibacterium acnes (formerly known as Propionibacterium acnes) is the only bacterium that has consistently been isolated from sarcoid lesions (2), and its presence has been confirmed by molecular studies, including PCR and in situ hybridization (3–5). Negi et al. (6) demonstrated the localization of C. acnes in granulomas, and Eishi (7) subsequently reviewed the etiologic link. However, outside of Japan, other microorganisms, including mycobacterial antigens, have also been implicated, and the etiology of sarcoidosis remained unresolved until date (8–11). Although the etiology of sarcoidosis remains unresolved until now, Sawahata et al. (12) recently reviewed latent microbial reactivation and immune dysregulation in sarcoidosis, focusing on C. acnes.
Sarcoidosis can affect multiple organs, including the lungs, lymph nodes, heart, eyes, and skin. Pulmonary involvement is of major clinical significance, as the lesions could progress to intractable fibrosis and cyst formation in the lungs. This review describes the pathological diversity of sarcoid lesions in the lungs, with particular emphasis on pulmonary fibrosis and vascular involvement, mainly based on autopsy of cases of Japanese patients with sarcoidosis.
2 Incidence and characterization of sarcoidosis in Japan
Ethnic differences are known to exist in the clinical features of sarcoidosis. Recent epidemiological surveys in Japan (13) have revealed that sarcoidosis occurs at an incidence of 1.01 per 100,000 population in Japan with a male-to-female ratio of 0.73:1.28. Morimoto reported a peak prevalence of sarcoidosis between 20 and 34 years of age in men and between 50 and 69 years of age in women (13). The organs most frequently affected, in addition to the lungs, are the eyes, skin, and heart. Sawahata et al. (14, 15) analyzed the relationship between the stage of illness based on diagnostic imaging findings and age and found that stage 1 or 2 predominantly occur in persons 45 years old or under and that stage 3 and 4 diseases predominantly occur in the elderly age group.
Iwai et al. (16, 17) investigated the autopsy findings of sarcoidosis in Japan between 1958 and 1989 and reported that both the distribution of granulomas in the body and the fatality rate tended to be higher among cases with cardiac sarcoidosis. Tachibana conducted autopsy investigations of sarcoidosis in patients who had died at 80 years later and reported that a high percentage of the patients had died from cardiac lesions (77%), and that malignant neoplasm was the most frequent cause of death after sarcoidosis in these patients (18).
3 Biopsy techniques for the diagnosis of pulmonary sarcoidosis
A Case-Controlled Etiologic Study of Sarcoidosis conducted in 2005 showed that biopsies of different sites of the body had been performed to make a definitive diagnosis of sarcoidosis (19). Biopsies within the thoracic cavity are the most frequently performed to identify non-caseating epithelioid cell granulomas. Since granulomas associated with various diseases can be detected in various organs, a differential diagnosis of sarcoidosis from other granulomatous diseases is necessary (20). The scalene lymph node biopsy was often used as a diagnostic procedure in the past, and then, the biopsy of the mediastinal lymph nodes by endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) has been often applied (21). Although granulomas can be identified and clearly diagnosed by EBUS-TBNA, evaluation of the entire lymph node structure is often difficult. At present, transbronchial lung biopsy and transbronchial lung cryobiopsy are the most frequently used procedures to diagnose pulmonary sarcoidosis (22).
4 Morphological characteristics of the granulomas
Granulomas in sarcoidosis are formed by the aggregation of macrophage-derived epithelioid cells as a result of a Th1 immune reaction induced by antigen presentation to T lymphocytes. This can be viewed as the morphological form of a host defense mechanism that isolates the body from the pathogens (11). Regulatory T cells and macrophages play a major role in granuloma formation (23, 24). Most of the granulomas in sarcoidosis consist of solitary granuloma measuring 200–300 μm in size or conglomerated ones composed of non-caseating epithelioid cells (25). Epithelioid cell granulomas are well demarcated from the surrounding tissues, and silver impregnation staining reveals argyrophilic fibers in a basket-like form. Well-developed subplasmalemmal linear densities are seen between adjacent epithelioid cells (Figure 1). The granulomas contain lymphocytes and Langhans giant cells in addition to epithelioid cells. CD4+ T lymphocytes are distributed within the granulomas, whereas CD8+ T lymphocytes are distributed at the margin of the granulomas. Granular substances have been detected in the sarcoid granulomas within the lung with the use of a monoclonal antibody to lipoteicoic acid of C. acnes (6, 7) (Figure 2).
Figure 1
Figure 2
4.1 Inclusion bodies in granulomas
The giant cells in sarcoid granulomas often contain inclusion bodies such as Schaumann bodies (conchoidal bodies) that measure 25–200 μm in size and possess a lamellar structure containing iron and calcium (Figure 3a). Schaumann bodies are very common in sarcoidosis, but they are also seen in the granulomas associated with tuberculosis, berylliosis, and occasionally, hypersensitivity pneumonitis. Asteroid bodies are star-shaped inclusion bodies noted within multinucleated giant cells that measure 5–30 μm in size and are arranged in a radiating manner; they are seen in 2–9% of all sarcoid granulomas (Figure 3b). Asteroid bodies are composed of ubiquitin and myelin sheath-like membranous material and can also be found in tuberculosis, histoplasmosis, lepromas, and foreign body granulomas (25).
Figure 3
4.2 Hyalinization and necrosis of granulomas
Most sarcoid granulomas regress spontaneously but persist in the form of hyalinized nodules (Figure 3c). The granulomas in sarcoidosis have generally been described as non-necrotic epithelioid cell granulomas, but necrosis within the granulomas of sarcoidosis has also been reported in approximately 3–30% of cases (25).
4.3 Fibrosis of granulomas
Most granulomas in sarcoidosis resolve when the antigen is eliminated. Some granulomas develop fibrosis, often with remaining giant cells and lymphocytes (Figure 3d). The process of fibrosis of granuloma in pulmonary sarcoidosis may be induced by a dysregulated immune response. Th1-mediated immune reaction results in activation of fibroblasts. Various fibrogenic cytokines, such as TGF-β, TNF-α, IL-1β, and IL-6, are derived from the constituent cells of granuloma, and they are considered to be fibrogenic factors (23, 26–29).
5 Distribution of sarcoid granulomas in the lung
The granulomas in pulmonary sarcoidosis are primarily distributed along the lymphatic vessels, namely in the bronchovascular bundles, bronchiolar walls, interlobular septa, and the pleura (Figure 4). Granulomas are also detected within the lymphatic vessels and in the alveoli. Analyses of transbronchial lung biopsy specimens have revealed that the granulomas in the lungs are predominantly distributed in the upper lobes (30). In nodular sarcoidosis, granulomas involve the alveolar lumina and destroy the alveolar architecture, often leading to intense fibrosis. Moreover, the granulomas around the bronchovascular bundles sometimes compress the bronchial and bronchiolar tree and cause upper lobe collapse.
Figure 4
6 Fibrotic sequelae in pulmonary sarcoidosis
Akira et al. (31) conducted long-term follow-up computed tomography evaluation of pulmonary sarcoidosis and showed peribronchial conglomeration with shrinkage of the lung. We conducted a pathological investigation of the fibrosis pattern and remodeling of the lungs in 66 autopsy cases of sarcoidosis in Japan (32).
6.1 Histological patterns of fibrosis associated with granulomas in the lung
The histological patterns of fibrosis associated with granuloma formations and remodeling of the lungs in sarcoidosis are shown in Table 1 (32). Stellate fibrosis is the most frequent type of fibrosis that occurs after the subsidence of a granuloma. Stellate fibrosis primarily occurs at the sites of granulomas along the bronchioles and pulmonary arteries and is also seen in the alveolar ducts (Figure 5a). Stellate fibrosis is the type of fibrosis seen in 95% of cases of pulmonary sarcoidosis and in 77% of cases in which the sarcoidosis does not predominantly affect the lungs, i.e., cardiac cases or nervous system. Bronchovascular fibrosis is observed primarily along the bronchioles and pulmonary arteries (Figure 5b) and was seen in 85% of cases of pulmonary sarcoidosis. Thick band-like collapse fibrosis (Figure 5c) was observed in 70% of cases of pulmonary sarcoidosis.
Table 1
| Stellate fibrosis (%) | Band-like fibrosis (%) | Bronchovascular bundle fibrosis (%) | Collapse of bronchovascular bundle (%) | Upper lobe contraction (%) | Cavity (%) | Bulla (%) | Bronchiectasis (%) | Honeycombing (%) | |
|---|---|---|---|---|---|---|---|---|---|
| Pulmonary sarcoidosis (n = 20) | 19 (95) | 17 (85) | 16 (80) | 14 (70) | 13 (65) | 9 (45) Aspergillus 8 (40) | 11 (55) | 13 (65) | 10 (50) |
| Cardiac sarcoidosis (n = 31) | 21 (68) | 8 (26) | 13 (42) | 5 (16) | 10 (32) | 1 (3) | 5 (16) | 1 (3) | 1 (3) |
| Neurosarcoidosis (n = 3) | 3 (100) | 0 | 3 (100) | 2 (67) | 2 (67) | 0 | 0 | 0 | 1 (33) |
| Sarcoidosis without special organ involvement (n = 12) | 8 (67) | 3 (25) | 6 (50) | 4 (33) | 1 (8) | 0 | 0 | 1 (8) | 1 (8) |
| Total 66 (female 45, male 21) | 51 (77) | 28 (42) | 38 (58) | 25 (38) | 26 (39) | 10 (15) Aspergillus 8 (12) | 16 (24) | 15 (23) | 13 (20) |
Pathological features of the lung in 66 autopsy cases of sarcoidosis (32).
Figure 5
6.2 Bronchovascular bundle fibrosis and its sequelae
Bronchovascular bundle fibrosis develops predominantly in the upper lobes, resulting in contraction of the upper lobes of the lungs. Sawahata et al. (33) recently reported characteristic central-peripheral fibrotic bands with upper lobe shrinkage in patients with long-standing sarcoidosis. Kawanobe et al. (34) also described central bronchial deformity on chest radiographs in pulmonary sarcoidosis as a crucial phenotype of upper lobe fibrotic changes. Upper lobe contraction has been estimated to occur in 65% of cases of pulmonary sarcoidosis and 32% of cases with cf. cardiac sarcoidosis. These cases present segmental bronchial stenosis secondary to hilar lymph node enlargement and bronchovascular bundle fibrosis (Figures 6a,b). Among the 13 cases of pulmonary sarcoidosis that presented with upper lobe contraction, 9 cases exhibited cavity formation as well. These nine cases were accompanied by Aspergillus. Cyst formation was noted in 11 cases (55%) of pulmonary sarcoidosis (Table 1). The cystic lesions are likely a result of check-valve mechanisms that develop as a result of advanced fibrosis of the wall of the proximal bronchi.
Figure 6
6.3 Honeycomb lesions in pulmonary sarcoidosis
The honeycomb lesions in sarcoidosis are not confined to the lower lobe of the lung and often predominate in the upper lobe (Figures 7a,b) (35). Histologically, the normal alveolar architecture is lost, replaced by enlarged airspaces, connecting to bronchioles without the obviously collapsed perilobular alveoli, seen in usual interstitial pneumonia (UIP) (Figure 7c). However, Shigemitsu et al. reported (36, 37) some cases of pulmonary sarcoidosis showing honeycombing with fibroblastic foci in the lower lobe, resembling those of idiopathic pulmonary fibrosis.
Figure 7
Coexistence of sarcoidosis and interstitial pneumonia has been reported (38, 39). Tachibana also reported acute exacerbation occurring in cases with lower lung-dominant sarcoidosis (40).
7 Vascular involvement in pulmonary sarcoidosis
7.1 Granulomatous angiitis and its sequelae
Granulomatous vascular involvement is one of the characteristic lesions of pulmonary sarcoidosis (41, 42). Granulomatous angiitis associated with sarcoidosis is characterized by granuloma formation in the vascular wall with destruction of the elastic fibers and/or smooth muscles of the vascular wall; no neutrophil infiltration or necrosis is observed. Vascular involvement with granuloma formation has been observed in transbronchial lung biopsy specimens (30), as well as autopsy specimens (42). Granulomatous involvement and its sequelae extend from the larger blood vessels, namely the pulmonary arteries and veins in the hilar region to the smaller blood vessels throughout the lung, with particularly marked involvement of the interlobular veins and intralobular arteries (42) (Figure 8). Scarring of the vascular wall resulting from healing of granulomatous angiitis was often noted in autopsied lungs, without the regeneration of the elastic fibers and smooth muscles of the vascular wall destroyed by granuloma formation and prominent deposition of collagen fibers.
Figure 8
Pulmonary hypertension in sarcoidosis has been known as sarcoidosis-associated pulmonary hypertension (SAPH) and is an important complication of advanced sarcoidosis (43). SAPH may be induced by multifaceted causes, such as granulomatous angiitis, veno-occlusive disease, pulmonary embolism, interstitial lung disease, and extrapulmonary disease, including left ventricular systolic and diastolic dysfunction. Thus, the cases with granulomatous vascular involvement must be carefully followed up to develop into pulmonary hypertension.
7.2 Microangiopathy in sarcoidosis
Microangiopathy in sarcoidosis has been observed clinically in the form of vascular lesions in the ocular fundus, a hexagonal pattern of dilatation of the bronchial mucosal vessels, and Raynaud’s phenomenon in the skin. Electron microscopic observations have revealed endothelial cell degeneration and multilayering of the basement membranes of small blood vessels (30, 44, 45) (Figure 9). Microangiopathic changes have been observed in the myocardium, skin, skeletal muscles, and bronchial mucosa in patients with sarcoidosis. In regard to the etiology of microangiopathy associated with sarcoidosis, it has been considered that vascular endothelial cell growth factors released from the constituent cells of granuloma and their receptors in the microcirculation system could be involved (46). However, further studies of microangiopathy are needed.
Figure 9
8 Conclusion
I acknowledge that this pathological review of pulmonary sarcoidosis is limited to the Japanese patients, especially regarding the Japanese autopsy cases of sarcoidosis. In this paper, we have described the pathological features in the lung in patients with sarcoidosis, focusing on various fibrotic sequelae of epithelioid cell granulomas and remodeling of the lung. Granuloma-derived fibrosis predominantly involves the upper lobe bronchi from the hilar region to the pleura, resulting in upper lobe contraction and occasionally, formation of honeycomb-like lesions. Figure 10 shows a scheme of multifaceted pulmonary lesions derived from granulomas in sarcoidosis. Further research is necessary to resolve the process from granuloma to fibrosis and to prevent progressive fibrosis in pulmonary sarcoidosis.
Figure 10
Statements
Author contributions
TT: Writing – review & editing, Investigation, Writing – original draft.
Funding
The author(s) declare that no financial support was received for the research and/or publication of this article.
Conflict of interest
The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author declare that no Gen AI was used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1.
HunninghakeGWCostabelUAndoMBaughmanRCordierJFdu BoisRet al. Statement on sarcoidosis. Joint statement of the American Thoracic Society (ATS) and the European respiratory society (ERS) and the world association of sarcoidosis and other granulomatous disorders (WASOG) adopted by the ATS board of directors and by the ERS executive committee, February 1999. Am J Respir Crit Care Med. (1999) 160:736–55. doi: 10.1164/ajrccm.160.2.ats4-99
2.
AbeCIwaiKMikamiRHosodaY. Frequent isolation of Propionibacterium acnes from sarcoidosis lymph nodes. Zentralbl Bakteriol Mikrobiol Hyg A. (1984) 256:541–7. doi: 10.1016/s0174-3031(84)80032-3
3.
IshigeIUsuiYTakemuraTEishiY. Quantitative PCR of mycobacterium and propionibacterial DNA in lymph nodes of Japanese patients with sarcoidosis. Lancet. (1999) 354:120–3. doi: 10.1016/S0140-6736(98)12310-3
4.
EishiYSugaMIshigeIKobayashiDYamadaTTakemuraTet al. Quantitative analysis of mycobacterial and propionibacterial DNA in lymph nodes of Japanese and European patients with sarcoidosis. J Microbiol. (2002) 40:198–204. doi: 10.1128/JCM.40.1.198-204.2002
5.
YamadaTEishiYIkedaSIshigeISuzukiTTakemuraTet al. In situ localization of Propionibacterium acnes DNA in lymph nodes from sarcoidosis patients by signal amplification with catalysed reporter deposition. J Pathol. (2002) 198:541–7. doi: 10.1002/path.1243
6.
NegiMTakemuraTGuzmanJUchidaKFurukawaASuzukiYet al. Localization of Propionibacterium acnes in granulomas support a possible etiologic link between sarcoidosis and bacterium. Mod Pathol. (2012) 25:1284–97. doi: 10.1038/modpathol.2012.80
7.
EishiY. Etiologic aspect of sarcoidosis as an allergic endogenous infection caused by Propionibacyerium acnes. Respir Investig. (2013) 51:56–68. doi: 10.1155/2013/935289
8.
SongZMarzilliLGreenleeBMChenESSilverRFAskinFBet al. Mycobacterial catalases peroxidase is a tissue antigen and target of the adaptive immune response in systemic sarcoidosis. J Exp Med. (2005) 201:755–67. doi: 10.1084/jem.20040429
9.
DubaniewiczADubaniewicz-WybieralskaMSternauAZwolskaZIzycka-SwieszewskaEAugustynowicz-KopecEet al. Mycobacterium tuberculosis complex and mycobacterial heat shock proteins in lymph node tissue from patients with pulmonary sarcoidosis. J Clin Microbiol. (2006) 44:3448–51. doi: 10.1128/JCM.01433-06
10.
MollerDR. Potential etiologic agents in sarcoidosis. Proc Am Thorac Soc. (2007) 4:465–8. doi: 10.1513/pats.200608-155MS
11.
GrunewaldJGruttersJCArkemaEArkemaEVSaketkooLAMollerDRet al. Sarcoidosis. Nat Rev Dis Primers. (2019) 5:45. doi: 10.1038/s41572-019-0096-x
12.
SawahataMUchidakFurukawaAEishiYMaemondoM. Latent microbial reactivation and immune dysregulation in sarcoidosis; bridging pathogenesis and precision therapeutics. Front Med. (2025) 12:1625915. doi: 10.3389/fmed.2025.1625915
13.
MorimotoTAzumaAAbeSUsukiJKudohSSugisakiKet al. Epidemiology of sarcoidosis in Japan. Eur Respir J. (2008) 31:372–9. doi: 10.1183/09031936.00075307
14.
SawahataMSugiyamaYNakamuraYNakayamaMMatoNYamasawaHet al. Age-related differences in chest radiographic staging of sarcoidosis in Japan. Eur Respir J. (2014) 43:1810–2. doi: 10.1183/09031936.00005414
15.
SawahataMSugiyamaYNakamuraYNakayamaMMatoNYamasawaHet al. Age-related and historical changes in the clinical characteristics of sarcoidosis in Japan. Respir Med. (2015) 109:272–8. doi: 10.1016/j.rmed.2014.12.012
16.
IwaiKTachibanaTTakemuraTMatsuiYKitalchiMKawabataY. Pathological studies on sarcoidosis autopsy. I. Epidemiological features of 320 cases in Japan. Acta Pathol Jpn. (1993) 43:372–6. doi: 10.1111/j.1440-1827.1993.tb01148.x
17.
IwaiKTakemuraTKitaichiMKawabataYMatsuiY. Pathological studies on sarcoidosis autopsy. Part II. Early change, mode pf progression and death pattern. Acta Pathol Jpn. (1993) 43:377–85. doi: 10.1111/j.1440-1827.1993.tb01149.x
18.
TachibanaTIwaiKTakemuraT. Sarcoidosis in the aged: review and management. Curr Opin Pulm Med. (2010) 16:465–71. doi: 10.1097/MCP.0b013e32833ae508
19.
TeirsteinASJudsonMABaughmanRPRossmanMDYeagerHJrMollerDR. The spectrum of biopsy sites for the diagnosis of sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. (2005) 22:139–46.
20.
CrouserEDMaierLAWilsonKCBonhamCAMorgenthauASPattersonKCet al. Diagnosis and detection of sarcoidosis. An official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med. (2020) 201:e26–51. doi: 10.1164/rccm.202002-0251ST
21.
NakajimaTYasufukuKKurosuKTakiguchiYFujiwaraTChiyoMet al. The role of EBUS-TBNA for the diagnosis of sarcoidosis-comparison with other bronchoscopic diagnostic modalities. Respir Med. (2009) 103:1796–800. doi: 10.1016/j.rmed.2009.07.013
22.
HetzelJMaldonadoFRavagliaCWellsAUColbyTVTomassettiSet al. Transbronchial cryobiopsies for the diagnosis of diffuse parenchymal lung diseases: expert statement from the cryobiopsies working group on safety and utility and a call for standardization of the procedure. Respiration. (2018) 95:188–200. doi: 10.1159/000484055
23.
ZhangHCostabelUHuangD. The role of diverse immune cells in sarcoidosis. Front Immunol. (2021) 12:788502. doi: 10.3389/fimmu.2021.788502
24.
XuDTaoXFanYTengY. Sarcoidosis: molecular mechanisms and therapeutic strategies. Mol Biomed. (2025) 6:6. doi: 10.1186/s43556-025-00244-z
25.
RosenY. Sarcoidosis In: DailDHHammarSP, editors. Pulmonary pathology. New York: Springer-Verlag (1993). 615.
26.
BonhamCAStrekMEPattersonKC. From granuloma to fibrosis: sarcoidosis associated pulmonary fibrosis. Curr Opin Pulm Med. (2016) 22:484–91. doi: 10.1097/MCP.0000000000000301
27.
WeeratungaPMollerDRHoLP. Immune mechanisms in fibrotic pulmonary sarcoidosis. Eur Respir Rev. (2022) 31:220178. doi: 10.1183/16000617.0178-2022
28.
BandyopadhyayDMirsaeidiMS. Sarcoidosis-associated pulmonary fibrosis: joining the dots. Eur Respir Rev. (2023) 32:230085. doi: 10.1183/16000617.0085-2023
29.
NunesHBrilletP-YBernaudinJ-FGilleTValeyreDJenyF. Fibrotic pulmonary sarcoidosis. Clin Chest Med. (2024) 45:199–212. doi: 10.1016/j.ccm.2023.08.011
30.
TakemuraTMatsuiYOritsuMAkiyamaOHiragaYOmichiMet al. Pulmonary vascular involvement in sarcoidosis: granulomatous angiitis and microangiopathy in transbronchial lung biopsies. Virchows Arch A Pathol Anat Histopathol. (1991) 418:361–8. doi: 10.1007/BF01600167
31.
AkiraMKozukaTInoueYSakataniM. Long-term follow-up CT scan evaluation in patients with pulmonary sarcoidosis. Chest. (2005) 127:185–91. doi: 10.1378/chest.127.1.185
32.
TakemuraTIkushimaSAndoTYanagawaTAkiyamaOOritsuMet al. Remodeling of the lung in sarcoidosis: a pathological study of 66 autopsy cases. Jpn J Sarcoidosis Other Granulomatous Disord. (2003) 23:43–52. doi: 10.14830/jssog1999.23.43
33.
SawahataMJohkohTKawanobeTKonoCNakamuraYBandoMet al. Computed tomography images of fibtrooic pulmonary sarcoidosis leading to chronic respiratory failure. J Clin Med. (2020) 9:142. doi: 10.3390/jcm9010142
34.
KawanobeTYamaguchiTJohkohTKonoCSawahataMShijuboNet al. Central bronchial deformity in pulmonary sarcoidosis: a finding suggestive of an upper lobe fibrotic phenotype on chest images. Acad Radiol. (2024) 31:1160–7. doi: 10.1016/j.acra.2023.08.034
35.
TakemuraTEishiYMatsuiY. An autopsy case of sarcoidosis followed up for 27 years with special reference to pulmonary fibrosis. Acta Pathol Jpn. (1988) 38:909–20. doi: 10.1111/j.1440-1827.1988.tb02362.x
36.
ShigemitsuHObladJMSharmaOPKossMN. Chronic interstitial pneumonitis in end-stage sarcoidosis. Eur Respir J. (2010) 35:695–7. doi: 10.1183/09031936.00150609
37.
ShigemitsuHAzumaA. Sarcoidosis and interstitial pulmonary fibrosis; two distinct disorders or two ends of the same spectrum. Curr Opin Pulm Med. (2011) 17:303–7. doi: 10.1097/MCP.0b013e3283486d52
38.
TachibanaKAraiTKagawaTMinomoSAkiraMKitaichiMet al. A case of combined sarcoidosis and usual interstitial pneumonia. Intern Med. (2012) 51:1893–7. doi: 10.2169/internalmedicine.51.7394
39.
CollinsBFMcClellandRLHoLAMikacenicCRHayesJSpadaCet al. Sarcoidosis and IPF in the same patient-a coincidence, an association or a phenotype?Respir Med. (2018) 144:S20–7. doi: 10.1016/j.rmed.2018.08.008
40.
TachibanaKAkiraMAraiTSugimotoCHayashiSInoueY. Poor outcome and mortality in patients with lower lung-dominant sarcoidosis. Can Respir J. (2023) 2023:3624344. doi: 10.1155/2023/3624344
41.
RosenYMoonSHuangCTGourinALyonsHA. Granulomatous pulmonary angiitis in sarcoidosis. Arch Pathol Lab Med. (1977) 101:170–4.
42.
TakemuraTSaikiSMatsuiYMikamiR. Pulmonary vascular involvement in sarcoidosis: a report of 40 autopsy cases. Hum Pathol. (1992) 23:1216–23. doi: 10.1016/0046-8177(92)90288-e
43.
SavaleLHuitemaMShlobinOKouranosVNathanSDNunesHet al. WASOG statement on the diagnosis and management of sarcoidosis-associated pulmonary hypertension. Eur Respir Rev. (2022) 31:210165. doi: 10.1183/16000617.0165-2021
44.
MikamiRSekiguchiMRyuzinYKobayashiFHiragaYShimadaYet al. Changes in peripheral vasculature of various organs in patients with sarcoidosis. –possible role of microangiopathy. Heart Vessel. (1986) 2:129–39. doi: 10.1007/BF02128138
45.
TakemuraTHiragaYOomichiMOritsuMAkiyamaOMatsuiYet al. Ultrastructural features of alveolitis in sarcoidosis. Am J Respir Crit Care Med. (1995) 152:360–6. doi: 10.1164/ajrccm.152.1.7599846
46.
MeyerKCKaminskiMJCalhounWJAuerbachR. Studies of bronchoalveolar lavage cells and fluids in pulmonary sarcoidosis. I. Enhanced capacity of bronchoalveolar lavage cells from patients with pulmonary sarcoidosis to induce angiogenesis in vivo. Am Rev Respir Dis. (1989) 140:1446–9. doi: 10.1164/ajrccm/140.5.1446
Summary
Keywords
sarcoidosis, lung, epithelioid cell granuloma, fibrosis, granulomatous angiitis, pathology
Citation
Takemura T (2025) Pathological diversity of pulmonary sarcoidosis. Front. Med. 12:1666973. doi: 10.3389/fmed.2025.1666973
Received
16 July 2025
Revised
29 October 2025
Accepted
13 November 2025
Published
27 November 2025
Volume
12 - 2025
Edited by
Yoshinobu Eishi, Tokyo Medical and Dental University, Japan
Reviewed by
Yasuo Shimizu, Dokkyo Medical University School of Medicine, Japan
Likhita Shaik, University of Iowa Sleep Disorders Center, United States
Updates
Copyright
© 2025 Takemura.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Tamiko Takemura, tamikobyori@gmail.com
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.